- At ProCyte, total revenues for the first three months of 1996 were $471,310, down $1 million from the same period last year. A net loss of $2 million and net loss per share of $0.16 was recorded. For the six months ended June 30, total revenues were $2.2 million, down 21.4%, with a net loss of $3.5 million, and net loss per share of $0.26.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze